# US 2021/0275679 A1 · Heparosan polymers and methods of making and using same for the enhancement of therpeutics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275679 A1
- Document ID: US20210275679A1
- Status: Published application
- Kind: A1
- Application number: 17/199,270
- Filed: 2021-03-11
- Published: 2021-09-09
- Earliest claimed: 2008-03-19
- Assignees: The Board of Regents of the University of Oklahoma
- Applicants: The Board of Regents of the University of Oklahoma
- Inventors: Paul L. DEANGELIS
- Web page: https://patentgrep.com/patent/US20210275679A1

## CPC

- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Compositions, methods, and systems for the development and use of heparosan as a therapeutic modifying agent or vehicle which can modulate drug cargo pharmacokinetics and behavior within a mammalian patient.

## Claims

### Claim 1

A non-immunogenic pharmaceutical drug delivery composition for treating a disease condition in a mammalian patient, the pharmaceutical composition comprising:
one or more heparosan-drug conjugates, wherein each conjugate comprises:
at least one heparosan polymer, wherein the at least one heparosan polymer is unsulfated; and
at least one therapeutic non-peptide drug conjugated to the at least one heparosan polymer, wherein the at least one therapeutic non-peptide drug treats a mammalian disease condition and remains active when conjugated to the at least one heparosan polymer; and
a pharmaceutically acceptable carrier; and
wherein the pharmaceutical drug delivery composition is a sterile pharmaceutical formulation in a unit dosage format.

### Claim 2 (depends on 1)

The pharmaceutical drug delivery composition of claim 1, wherein the at least one therapeutic non-peptide drug does not increase immunoreactivity of the at least one heparosan polymer.

### Claim 3 (depends on 1)

The pharmaceutical drug delivery composition of claim 1, wherein the at least one therapeutic non-peptide drug is not an adjuvant.

### Claim 4 (depends on 1)

The pharmaceutical drug delivery composition of claim 1, wherein each heparosan-drug conjugate comprises a single heparosan polymer conjugated to the at least one therapeutic non-peptide drug.

### Claim 5 (depends on 1)

The pharmaceutical drug delivery composition of claim 1, wherein each heparosan-drug conjugate comprises a plurality of heparosan polymers conjugated to the at least one therapeutic non-peptide drug.

### Claim 6 (depends on 1)

The pharmaceutical drug delivery composition of claim 1, wherein the at least one heparosan polymer has a mass in a range of from about 600 Da to about 800 kDa.

### Claim 7 (depends on 1)

The pharmaceutical drug delivery composition of claim 1, wherein the at least one heparosan polymer is unepimerized.

### Claim 8 (depends on 1)

The pharmaceutical drug delivery composition of claim 1, further defined as comprising a plurality of heparosan-drug conjugates, and wherein the plurality of heparosan polymers present in the conjugates is polydisperse in size.

### Claim 9 (depends on 1)

The pharmaceutical drug delivery composition of claim 1, further defined as comprising a plurality of heparosan-drug conjugates, and wherein the plurality of heparosan polymers present in the conjugates is substantially monodisperse in size.

### Claim 10 (depends on 1)

The pharmaceutical drug delivery composition of claim 1, wherein the at least one heparosan polymer has a linear polymer chain.

### Claim 11 (depends on 1)

The pharmaceutical drug delivery composition of claim 1, wherein the at least one heparosan polymer has a branched geometry.

### Claim 12 (depends on 1)

The pharmaceutical drug delivery composition of claim 1, wherein the at least one heparosan polymer has a half-life of at least 15 hours within extracellular compartments of the mammalian patient.

### Claim 13 (depends on 1)

The pharmaceutical drug delivery composition of claim 1, wherein at least one of:
(a) the pharmaceutical drug delivery composition exhibits increased retention in blood and/or lymphatic circulation of a mammalian patient when compared to therapeutic non-peptide drug alone;
(b) the pharmaceutical drug delivery composition exhibits reduced occurrence of accumulation in healthy organs and/or tissues of a mammalian patient when compared to therapeutic non-peptide drug alone;
(c) the pharmaceutical drug delivery composition exhibits higher accumulation in tumors and/or diseased tissues of a mammalian patient when compared to therapeutic non-peptide drug alone; and
(d) the at least one heparosan polymer is further characterized as being substantially non-targeting.

### Claim 14 (depends on 1)

The pharmaceutical drug delivery composition of claim 1, wherein the at least one heparosan polymer comprises an activated group on the at least one heparosan polymer to effect the conjugation of the at least one heparosan polymer to the therapeutic non-peptide drug, and wherein the reactive group is selected from the group consisting of an aldehyde, alkyne, ketone, maleimide, thiol, azide, amino, carbonyl, sulfhydryl, hydrazide, phosphate, sulfate, nitrate, carbonate, ester, squarate, chelator, and combinations thereof.

### Claim 15 (depends on 1)

The pharmaceutical drug delivery composition of claim 1, wherein the at least one heparosan polymer and the at least one therapeutic non-peptide drug are covalently conjugated.

### Claim 16 (depends on 1)

The pharmaceutical drug delivery composition of claim 1, wherein the at least one therapeutic non-peptide drug is selected from the group consisting of a chemotherapy agent, an antineoplastic agent, a steroid, an antibiotic, an anti-inflammatory agent, an agent that has an action on a central nervous system of the mammalian patient, an antihistaminic, an antiallergic agent, an antipyretic, a respiratory agent, an antimicrobial agent, an antihypertensive agent, a calcium antagonist, an antipsychotic, an agent for Parkinson's disease, a vitamin, an antitumor agent, a cholinergic agonist, a mydriatic, an antidepressant agent, an antidiabetic drug, an anorectic agent, an antimalarial agent, a hormone, an antiulcerative agent, an anticancer agent, a vaccine antigen, a polynucleotide, a nutrient, a small molecule, and combinations thereof.

### Claim 17 (depends on 1)

The pharmaceutical drug delivery composition of claim 1, wherein the at least one therapeutic non-peptide drug comprises an anti-cancer agent.

### Claim 18 (depends on 17)

The pharmaceutical drug delivery composition of claim 17, wherein the anti- cancer agent comprises cis-platin, actinomycin D, doxorubicin, vincristine, vinblastine, etoposide, amsacrine, mitoxantrone, tenipaside, taxol, colchicine, cyclosporin A, phenothiazines or thioxantheres.
